158 related articles for article (PubMed ID: 37722356)
41. Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician.
Byrd JC; Jones JJ; Woyach JA; Johnson AJ; Flynn JM
J Clin Oncol; 2014 Sep; 32(27):3039-47. PubMed ID: 25049322
[TBL] [Abstract][Full Text] [Related]
42. Patients' priorities in selecting chronic lymphocytic leukemia treatments.
Mansfield C; Masaquel A; Sutphin J; Weiss E; Gutierrez M; Wilson J; Boeri M; Li J; Reyes C
Blood Adv; 2017 Nov; 1(24):2176-2185. PubMed ID: 29296865
[TBL] [Abstract][Full Text] [Related]
43. Epidemiology and ethnic aspects of B cell chronic lymphocytic leukemia in Israel.
Shvidel L; Shtarlid M; Klepfish A; Sigler E; Berrebi A
Leukemia; 1998 Oct; 12(10):1612-7. PubMed ID: 9766507
[TBL] [Abstract][Full Text] [Related]
44. Novel Therapies for Chronic Lymphocytic Leukemia: A Canadian Perspective.
Owen C; Assouline S; Kuruvilla J; Uchida C; Bellingham C; Sehn L
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):627-634.e5. PubMed ID: 26416145
[TBL] [Abstract][Full Text] [Related]
45. Incidence of chronic lymphocytic leukemia and high-count monoclonal B-cell lymphocytosis using the 2008 guidelines.
Call TG; Norman AD; Hanson CA; Achenbach SJ; Kay NE; Zent CS; Ding W; Cerhan JR; Rabe KG; Vachon CM; Hallberg EJ; Shanafelt TD; Slager SL
Cancer; 2014 Jul; 120(13):2000-5. PubMed ID: 24711224
[TBL] [Abstract][Full Text] [Related]
46. Real-world clinical experience in the Connect
Mato A; Nabhan C; Kay NE; Weiss MA; Lamanna N; Kipps TJ; Grinblatt DL; Flinn IW; Kozloff MF; Flowers CR; Farber CM; Kiselev P; Swern AS; Sullivan K; Flick ED; Sharman JP
Br J Haematol; 2016 Dec; 175(5):892-903. PubMed ID: 27861736
[TBL] [Abstract][Full Text] [Related]
47. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study.
Fink AM; Bahlo J; Robrecht S; Al-Sawaf O; Aldaoud A; Hebart H; Jentsch-Ullrich K; Dörfel S; Fischer K; Wendtner CM; Nösslinger T; Ghia P; Bosch F; Kater AP; Döhner H; Kneba M; Kreuzer KA; Tausch E; Stilgenbauer S; Ritgen M; Böttcher S; Eichhorst B; Hallek M
Lancet Haematol; 2017 Oct; 4(10):e475-e486. PubMed ID: 28916311
[TBL] [Abstract][Full Text] [Related]
48. Treatment of elderly patients with chronic lymphocytic leukemia: an unmet cinical need.
Molica S; Brugiatelli M; Morabito F; Ferrara F; Iannitto E; Di Renzo N; Capalbo S; Musto P; Di Raimondo F
Expert Rev Hematol; 2013 Aug; 6(4):441-9. PubMed ID: 23991930
[TBL] [Abstract][Full Text] [Related]
49. Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: the Attenuated dose Rituximab with ChemoTherapy In Chronic lymphocytic leukaemia (ARCTIC) trial.
Howard DR; Munir T; McParland L; Rawstron AC; Chalmers A; Gregory WM; O'Dwyer JL; Smith A; Longo R; Varghese A; Smith A; Hillmen P
Health Technol Assess; 2017 May; 21(28):1-374. PubMed ID: 28628003
[TBL] [Abstract][Full Text] [Related]
50. Chronic lymphocytic leukemia (CLL) treatment: So many choices, such great options.
Sharma S; Rai KR
Cancer; 2019 May; 125(9):1432-1440. PubMed ID: 30807655
[TBL] [Abstract][Full Text] [Related]
51. Chronic lymphocytic leukemia treatment.
Dighiero G
Hematol Cell Ther; 1997 Nov; 39 Suppl 1():S31-40. PubMed ID: 9471059
[TBL] [Abstract][Full Text] [Related]
52. Dynamic Bayesian networks for prediction of health status and treatment effect in patients with chronic lymphocytic leukemia.
Ladyzynski P; Molik M; Foltynski P
Sci Rep; 2022 Feb; 12(1):1811. PubMed ID: 35110619
[TBL] [Abstract][Full Text] [Related]
53. Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States.
Chen Q; Jain N; Ayer T; Wierda WG; Flowers CR; O'Brien SM; Keating MJ; Kantarjian HM; Chhatwal J
J Clin Oncol; 2017 Jan; 35(2):166-174. PubMed ID: 27870563
[TBL] [Abstract][Full Text] [Related]
54. Epidemiology of Hematologic Malignancies in Real-World Settings: Findings From the Hemato-Oncology Latin America Observational Registry Study.
Tietsche de Moraes Hungria V; Chiattone C; Pavlovsky M; Abenoza LM; Agreda GP; Armenta J; Arrais C; Avendaño Flores O; Barroso F; Basquiera AL; Cao C; Cugliari MS; Enrico A; Foggliatto LM; Galvez KM; Gomez D; Gomez A; de Iracema D; Farias D; Lopez L; Mantilla WA; Martínez D; Mela MJ; Miguel CE; Ovilla R; Palmer L; Pavlovsky C; Ramos C; Remaggi G; Santucci R; Schusterschitz S; Sossa CL; Tuna-Aguilar E; Vela J; Santos T; de la Mora O; Machnicki G; Fernandez M; Barreyro P
J Glob Oncol; 2019 Nov; 5():1-19. PubMed ID: 31774711
[TBL] [Abstract][Full Text] [Related]
55. Canadian evidence-based guideline for frontline treatment of chronic lymphocytic leukemia: 2022 update.
Owen C; Banerji V; Johnson N; Gerrie A; Aw A; Chen C; Robinson S
Leuk Res; 2023 Feb; 125():107016. PubMed ID: 36634577
[TBL] [Abstract][Full Text] [Related]
56. Management of chronic lymphocytic leukaemia.
Kalil N; Cheson BD
Drugs Aging; 2000 Jan; 16(1):9-27. PubMed ID: 10733261
[TBL] [Abstract][Full Text] [Related]
57. Patient, physician, and general population preferences for treatment characteristics in relapsed or refractory chronic lymphocytic leukemia: A conjoint analysis.
Landfeldt E; Eriksson J; Ireland S; Musingarimi P; Jackson C; Tweats E; Gaudig M
Leuk Res; 2016 Jan; 40():17-23. PubMed ID: 26654707
[TBL] [Abstract][Full Text] [Related]
58. A canadian perspective on the first-line treatment of chronic lymphocytic leukemia.
Owen C; Bence-Bruckler I; Chamakhi I; Toze C; Assaily W; Christofides A; Robinson S
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):303-13. PubMed ID: 25937158
[TBL] [Abstract][Full Text] [Related]
59. Diagnosis of Chronic Lymphocytic Leukemia Using iwCLL 2018 Compared with NCI-WG96 Criteria in Cipto Mangunkusumo Hospital: A Practical Consideration in Resource Limited Setting.
Sukrisman L; Rinaldi I
Acta Med Indones; 2022 Oct; 54(4):531-539. PubMed ID: 36624709
[TBL] [Abstract][Full Text] [Related]
60. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
Palanca-Wessels MC; Czuczman M; Salles G; Assouline S; Sehn LH; Flinn I; Patel MR; Sangha R; Hagenbeek A; Advani R; Tilly H; Casasnovas O; Press OW; Yalamanchili S; Kahn R; Dere RC; Lu D; Jones S; Jones C; Chu YW; Morschhauser F
Lancet Oncol; 2015 Jun; 16(6):704-15. PubMed ID: 25925619
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
